Therapeutic targets for gout

Drugs of the Future

Volumn 35, Issue 4, 2010, Pages 333-337

  Sorbera, L A ^a   Sharanya, S ^a   Dulsat, C ^a   Rosa, E ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANION TRANSPORT PROTEIN; ANTIINFLAMMATORY AGENT; APG 101 10; CANAKINUMAB; CASPASE 3; CELECOXIB; COLCHICINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 3; DICLOFENAC; FEBUXOSTAT; FYX 051; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; MULTIDRUG RESISTANCE PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; PURINE NUCLEOSIDE PHOSPHORYLASE; RDEA 594; RDEA 684; RECOMBINANT URICASE; RILONACEPT; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URATE ANION EXCHANGER 1; URATE OXIDASE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR; XOMA 052;

DISEASE COURSE; DRUG MECHANISM; DRUG TARGETING; GOUT; HUMAN; HYPERURICEMIA; REVIEW;

EID: 77954582395     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.04.1502253     Document Type: Review

References (26)

1. SM Disease Briefings: Gout (online publication). Updated 2010.
2. Richette, P., Bardin, T. Gout. Lancet 2010, 375(9711): 318-28.
3. Terkeltaub, R. Update on gout: New therapeutic strategies and options. Nat Rev Rheumatol 2010, 6(1): 30-8.
4. Schumacher, H.R. Jr. The pathogenesis of gout. Cleve Clin J Med 2008, 75(Suppl 5): S2-4.
5. Terkeltaub, R. Gout. Novel therapies for treatment of gout and hyper-uricemia. Arthritis Res Ther 2009, 11(4): 236-47.
6. Gaffo, A.L., Saag, K.G. Are glucocorticoids equivalent to NSAIDs for the treatment of gout flares? Nat Clin Pract Rheumatol 2009, 5(1): 12-3.
7. Winzer, M., Tausche, A.K., Aringer, M. Crystal-induced activation of the inflammasome: gout and pseudogout. Z Rheumatol 2009, 68(9): 733-9.
8. Sae-wong, C., Tansakul, P., Tewtrakul, S. Anti-inflammatory mechanism of Kaempferia parviflora in murine macrophage cells (RAW 264.7) and in experimental animals. J Ethnopharmacol 2009, 124(3): 576-80.
9. Pascual, E., Sivera, F. Therapeutic advances in gout. Curr Opin Rheumatol 2007, 19(2):122-7.
10. Martina, S.D., Vesta, K.S., Ripley, T.L. Etoricoxib: A highly selective COX-2 inhibitor. Ann Pharmacother 2005, 39(5): 854-62.
11. Martinon, F. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 2010, 233(1): 218-32.
12. Mottó, A., Olivé, A. Anti-IL-1 molecules: New comers and new indications. Joint Bone Spine 2010, 77(2):102-7.
13. Sundy, J.S. Progress in the pharmacotherapy of gout. Curr Opin Rheumatol 2010, 22(2):188-93.
14. Goldbach-Mansky, R. Blocking interleukin-1 in rheumatic diseases. Ann NY Acad Sci 2009, 1182: 111-23.
15. Reinders, M.K., van Roon, E.N., Jansen, T.L. et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009, 68(1): 51-6.
16. Chohan, S., Becker, M.A. Update on emerging urate-lowering therapies. Curr Opin Rheumatol 2009, 21(2): 143-9.
17. Silverman,W., Locovei, S., Dahl, G. Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol 2008, 295(3): C761-7.
18. Bantia, S., Parker, C., Upshaw, R. et al. Potent orally bioavailable purine nucleoside Phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes-A novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies. Int lmmunopharmacol 2010, Epub ahead of print.
19. Ho, M.C., Shi, W., Rinaldo-Matthis, A. et al. Four generations of transition-state analogues for human purine nucleoside phosphorylase. Proc Natl Acad Sci USA 2010, 107(11): 4805-12.
20. Takano, Y., Hase-Aoki, K., Horiuchi, H., Zhao, L., Kasahara, Y., Kondo, S., Becker, M.A. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005, 76(16): 1835-47.
21. Bhat, A., Naguwa, S.M., Cheema, G.S., Gershwin, M.E. Colchicine revisited. Ann NY Acad Sci 2009, 1173: 766-73.
22. Ryckman, C., Gilbert, C., de Médicis, R., Lussier, A., Vandal, K., Tessier, P.A. Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils. J Leukoc Biol 2004, 76(2): 433-40.
23. Dinour, D., Gray, N.K., Campbell, S. et al. Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol 2010, 21(1): 64-72.
24. Doherty, M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009, 48 (Suppl 2): ii2-ii8.
25. Anzai, N., Ichida, K., Jutabha, P. et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATvT (SLC2A9) in humans. J Biol Chem 2008, 283(40): 26834-8.
26. Reinders, M.K., Jansen, T.L. Management of hyperuricemia in gout: Focus on febuxostat. Clin Interv Aging 2010, 5: 7-18.